Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

APPOINTMENT OF CHAIRMAN OF THE BOARD AND THE SUPERVISORY COMMITTEE AND APPOINTMENT OF GENERAL MANAGER, CO-PRESIDENT, DEPUTY GENERAL MANAGER, CHIEF FINANCIAL OFFICER, SECRETARY TO THE BOARD AND REPRESENTATIVE OF SECURITIES AFFAIRS AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The fifth session of the board (the "Board") of directors (the "Director(s)") of Hangzhou Tigermed Consulting Co., Ltd. (the "Company") comprises Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu as executive Directors and Dr. Yang Bo, Mr. Liu Kai Yu Kenneth and Mr. Yuan Huagang as independent non-executive Directors.

APPOINTMENT OF CHAIRMAN OF THE BOARD AND THE SUPERVISORY COMMITTEE

The Board is pleased to announce that at the first meeting of the fifth session of the Board held on May 23, 2023 (the "Board Meeting"), the Board has considered and approved the appointment of Dr. Ye Xiaoping as the chairman of the fifth session of the Board and his term shall commence on the date of approval of the Board Meeting until the conclusion of the fifth session of the Board.

At the first meeting of the fifth session of the supervisory committee of the Company (the "Supervisory Committee") held on May 23, 2023 (the "Supervisory Committee Meeting"), the Supervisory Committee has considered and approved the appointment of Mr. Zhang Binghui as the chairman of the fifth session of the Supervisory Committee and his term shall commence on the date of approval of the Supervisory Committee Meeting until the conclusion of the fifth session of the Supervisory Committee.

APPOINTMENT OF GENERAL MANAGER, CO-PRESIDENT, DEPUTY GENERAL MANAGER, CHIEF FINANCIAL OFFICER, SECRETARY TO THE BOARD AND REPRESENTATIVE OF SECURITIES AFFAIRS

The Board is pleased to announce that at the Board Meeting, the Board has considered and approved the appointment of Ms. Cao Xiaochun as the general manager of the Company, Mr. Wu Hao as the co-president of the Company, Mr. Wen Zengyu as the deputy general manager of the Company, Ms. Yang Chengcheng as the chief financial officer of the Company, Ms. Li Xiaori as the secretary to the Board and Ms. Ruan Xinhui as the representative of securities affairs (證券事務代表) of the Company. The term of their appointments shall commence on the date of approval of the Board Meeting until the conclusion of the fifth session of the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The composition of the Board committees of the fifth session of the Board are as follows:

- (1) the audit committee of the Board will comprise Mr. Liu Kai Yu Kenneth, Dr. Yang Bo and Mr. Yuan Huagang, and will be chaired by Mr. Liu Kai Yu Kenneth;
- (2) the nomination committee of the Board will comprise Dr. Yang Bo, Mr. Wen Zengyu and Mr. Liu Kai Yu Kenneth, and will be chaired by Dr. Yang Bo;
- (3) the remuneration and evaluation committee of the Board will comprise Mr. Yuan Huagang, Mr. Liu Kai Yu Kenneth and Ms. Cao Xiaochun, and will be chaired by Mr. Yuan Huagang; and
- (4) the strategic development committee of the Board will comprise Dr. Ye Xiaoping, Mr. Wu Hao, Dr. Yang Bo and Mr. Yuan Huagang, and will be chaired by Dr. Ye Xiaoping.

By order of the Board

Hangzhou Tigermed Consulting Co., Ltd.

Ye Xiaoping

Chairman

Hong Kong, May 23, 2023

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Dr. Yang Bo, Mr. Liu Kai Yu Kenneth and Mr. Yuan Huagang.